Skip to content
value.today
Celularity Inc logo

Celularity Inc

Celularity Inc is listed today as Celularity Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Celularity Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$2 MPrivate placement after listing$2 to $10 million

Celularity Inc: Private sale, Oct 2025

Investors in this round

1 investor had bought by the notice of Nov 3, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $7 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Haines · Executive Officer · Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary
  • Joseph R. DosSantos · Executive Officer · Interim Chief Financial Officer
  • Robert J. Hariri · Executive Officer, Director · Chief Executive Officer and Chairman of the Board of Directors
  • Stephen A. Brigido · Executive Officer · President, Degenerative Disease
  • Diane A. Parks · Director
  • Geoffrey A. Ling · Director
  • Peter A. Diamandis · Director
  • Vincent A. LeVien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert J. Hariri, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 3, 2025. Read the notice at the SEC.

equity, optionsSEC
Jul 2025$2 MPrivate placement after listing$2 to $10 million

Celularity Inc: Private sale, Jul 2025

Investors in this round

1 investor had bought by the notice of Aug 5, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Haines · Executive Officer · Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary
  • Joseph R. DosSantos · Executive Officer · Chief Financial Officer
  • Robert J. Hariri · Executive Officer, Director · Chief Executive Officer and Chairman of the Board of Directors
  • Stephen A. Brigido · Executive Officer · President, Degenerative Disease
  • Diane A. Parks · Director
  • Geoffrey A. Ling · Director
  • Peter A. Diamandis · Director
  • Vincent A. LeVien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert J. Hariri, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2025. Read the notice at the SEC.

equity, optionsSEC
Jul 2025$1 MPrivate placement after listingUnder $2 million

Celularity Inc: Private sale, Jul 2025

Investors in this round

14 investors had bought by the notice of Aug 5, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Haines · Executive Officer · Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary
  • Joseph R. DosSantos · Executive Officer · Chief Financial Officer
  • Robert J. Hariri · Executive Officer, Director · Chief Executive Officer and Chairman of the Board of Directors
  • Stephen A. Brigido · Executive Officer · President, Degenerative Disease
  • Diane A. Parks · Director
  • Geoffrey A. Ling · Director
  • Peter A. Diamandis · Director
  • Vincent A. LeVien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert J. Hariri, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2025. Read the notice at the SEC.

equity, optionsSEC
Jul 2025$7 MPrivate placement after listing$2 to $10 million

Celularity Inc: Private sale, Jul 2025

Investors in this round

1 investor had bought by the notice of Aug 5, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John R. Haines · Executive Officer · Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary
  • Joseph R. DosSantos · Executive Officer · Chief Financial Officer
  • Robert J. Hariri · Executive Officer, Director · Chief Executive Officer and Chairman of the Board of Directors
  • Stephen A. Brigido · Executive Officer · President, Degenerative Disease
  • Diane A. Parks · Director
  • Geoffrey A. Ling · Director
  • Peter A. Diamandis · Director
  • Vincent A. LeVien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert J. Hariri, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2025. Read the notice at the SEC.

debt, optionsSEC
May 2022$30 MPrivate placement after listing$10 to $50 million

Celularity Inc: Private sale, May 2022

Investors in this round

1 investor had bought by the notice of May 27, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew L. Pecora · Executive Officer
  • Anne R. Jones · Executive Officer
  • Bradley A. Glover · Executive Officer
  • David C. Beers · Executive Officer
  • John R. Haines · Executive Officer
  • Keary A. Dunn · Executive Officer
  • Robert J. Hariri · Executive Officer, Director
  • Stephen A. Brigido · Executive Officer
  • Andrew C. von Eschenbach · Director
  • Dean C. Kehler · Director
  • Jay R. Bloom · Director
  • John R. Sculley · Director
  • Lim Kok Thay · Director
  • Marc Kok Mazur · Director
  • Peter R. Diamandis · Director
  • Robin L. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P/ Alliance Global Partners (CRD 8361) · New York, New YorkSold in NY

Signed by David Beers, Chief Financial Officer. Source: SEC Form D, newest notice filed May 27, 2022. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Celularity Inc., its revenue in fiscal 2025 came from these product and service lines: License Royalty and Other $7.94 million (30%).

    Annual report (SEC XBRL) · Dec 2025

  • Celularity Inc chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2025

Products and services#

No products or services of Celularity Inc are on record.

Investors#

No investor of Celularity Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Celularity Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Celularity Inc
NameRoleNamed in
John R. HainesSenior Executive Vice President, Chief Administrative Officer and Corporate SecretaryNov 2025
Joseph R. DosSantosInterim Chief Financial OfficerNov 2025
Robert J. HaririChief Executive Officer and Chairman of the Board of DirectorsNov 2025
Stephen A. BrigidoPresident, Degenerative DiseaseNov 2025
Andrew L. PecoraExecutive officerMay 2022
Anne R. JonesExecutive officerMay 2022
Bradley A. GloverExecutive officerMay 2022
David C. BeersExecutive officerMay 2022
Keary A. DunnExecutive officerMay 2022
Diane A. ParksDirectorNov 2025
Geoffrey A. LingDirectorNov 2025
Peter A. DiamandisDirectorNov 2025
Robert J. HaririChief Executive Officer and Chairman of the Board of DirectorsNov 2025
Vincent A. LeVienDirectorNov 2025
Andrew C. von EschenbachDirectorMay 2022
Dean C. KehlerDirectorMay 2022
Jay R. BloomDirectorMay 2022
John R. SculleyDirectorMay 2022
Lim Kok ThayDirectorMay 2022
Marc Kok MazurDirectorMay 2022
Peter R. DiamandisDirectorMay 2022
Robin L. SmithDirectorMay 2022

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.